Published in Proc Natl Acad Sci U S A on February 21, 2006
Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer (2009) 9.26
Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol (2011) 5.65
Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer (2010) 5.26
ChemBank: a small-molecule screening and cheminformatics resource database. Nucleic Acids Res (2007) 5.10
Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci U S A (2006) 3.83
Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators. Nat Biotechnol (2012) 3.65
Engineered luciferase reporter from a deep sea shrimp utilizing a novel imidazopyrazinone substrate. ACS Chem Biol (2012) 2.53
Combination chemical genetics. Nat Chem Biol (2008) 1.98
A robotic platform for quantitative high-throughput screening. Assay Drug Dev Technol (2008) 1.90
Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness. Nature (2016) 1.51
A structure-guided approach to creating covalent FGFR inhibitors. Chem Biol (2010) 1.46
Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett (2009) 1.26
Measuring and interpreting the selectivity of protein kinase inhibitors. J Chem Biol (2009) 1.24
High-throughput screening and chemical biology: new approaches for understanding circadian clock mechanisms. Chem Biol (2009) 1.21
A comparison of machine learning algorithms for chemical toxicity classification using a simulated multi-scale data model. BMC Bioinformatics (2008) 1.18
Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase. Bioorg Med Chem Lett (2008) 1.17
Colloidal aggregation affects the efficacy of anticancer drugs in cell culture. ACS Chem Biol (2012) 1.17
The Rab5 guanylate exchange factor Rin1 regulates endocytosis of the EphA4 receptor in mature excitatory neurons. Proc Natl Acad Sci U S A (2008) 1.15
Targeting Eph receptors with peptides and small molecules: progress and challenges. Semin Cell Dev Biol (2011) 1.11
Ten things you should know about protein kinases: IUPHAR Review 14. Br J Pharmacol (2015) 1.06
High-throughput in vivo screening of targeted molecular imaging agents. Proc Natl Acad Sci U S A (2009) 1.05
A type-II kinase inhibitor capable of inhibiting the T315I "gatekeeper" mutant of Bcr-Abl. J Med Chem (2010) 0.96
EphrinA2 receptor (EphA2) is an invasion and intracellular signaling receptor for Chlamydia trachomatis. PLoS Pathog (2015) 0.91
Connecting synthetic chemistry decisions to cell and genome biology using small-molecule phenotypic profiling. Curr Opin Chem Biol (2009) 0.90
An inhibitor-resistant mutant of Hck protects CML cells against the antiproliferative and apoptotic effects of the broad-spectrum Src family kinase inhibitor A-419259. Oncogene (2008) 0.88
Back to the future: lessons learned in modern target-based and whole-cell lead optimization of antimalarials. Curr Top Med Chem (2012) 0.88
Discovery of GNF-5837, a Selective TRK Inhibitor with Efficacy in Rodent Cancer Tumor Models. ACS Med Chem Lett (2012) 0.87
Cell-based optimization of novel benzamides as potential antimalarial leads. Bioorg Med Chem Lett (2009) 0.85
KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors. Cancer Res (2013) 0.84
Enhancing reproducibility in cancer drug screening: how do we move forward? Cancer Res (2014) 0.84
An image-based screen identifies a small molecule regulator of megakaryopoiesis. Proc Natl Acad Sci U S A (2012) 0.83
Functional genomics to uncover drug mechanism of action. Nat Chem Biol (2015) 0.82
Src-kinase inhibitors sensitize human cells of myeloid origin to Toll-like-receptor-induced interleukin 12 synthesis. Blood (2013) 0.82
A chemocentric approach to the identification of cancer targets. PLoS One (2012) 0.81
Broad spectrum alkynyl inhibitors of T315I Bcr-Abl. Bioorg Med Chem Lett (2010) 0.81
BCR-ABL signaling: A new STATus in CML. Nat Chem Biol (2012) 0.80
Low doses of imatinib induce myelopoiesis and enhance host anti-microbial immunity. PLoS Pathog (2015) 0.80
A combination of tyrosine kinase inhibitors, crizotinib and dasatinib for the treatment of glioblastoma multiforme. Oncotarget (2015) 0.79
The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and proliferation. Blood Cancer J (2011) 0.79
Completing the structural family portrait of the human EphB tyrosine kinase domains. Protein Sci (2014) 0.79
Fluorescent visualization of Src by using dasatinib-BODIPY. Chembiochem (2014) 0.78
An amino-indazole scaffold with spectrum selective kinase inhibition of FLT3, PDGFRα and kit. Bioorg Med Chem Lett (2012) 0.78
Computational Modeling of Kinase Inhibitor Selectivity. ACS Med Chem Lett (2010) 0.78
Discovery of RAF265: A Potent mut-B-RAF Inhibitor for the Treatment of Metastatic Melanoma. ACS Med Chem Lett (2015) 0.77
Cellular Ser/Thr-kinase assays using generic peptide substrates. Curr Chem Genomics (2008) 0.77
Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation. Oncotarget (2016) 0.77
Development of 'DFG-out' inhibitors of gatekeeper mutant kinases. Bioorg Med Chem Lett (2012) 0.77
(R)-2-Phenylpyrrolidine Substituted Imidazopyridazines: A New Class of Potent and Selective Pan-TRK Inhibitors. ACS Med Chem Lett (2015) 0.76
Targeting lymphatic vessel functions through tyrosine kinases. J Angiogenes Res (2010) 0.76
The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies. Trends Immunol (2016) 0.75
A Novel Triazolopyridine-Based Spleen Tyrosine Kinase Inhibitor That Arrests Joint Inflammation. PLoS One (2016) 0.75
Oncogenic kinase signalling. Nature (2001) 16.30
Overriding imatinib resistance with a novel ABL kinase inhibitor. Science (2004) 11.83
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell (2005) 7.99
Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol (2002) 6.92
Tyrosine kinases as targets for cancer therapy. N Engl J Med (2005) 6.24
Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell (1994) 4.64
A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science (1997) 4.29
Features of selective kinase inhibitors. Chem Biol (2005) 4.07
Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol (2002) 3.92
Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res (1996) 3.85
Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc Natl Acad Sci U S A (1988) 3.74
A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res (2003) 3.47
Identification and prediction of promiscuous aggregating inhibitors among known drugs. J Med Chem (2003) 3.44
Systems biology in drug discovery. Nat Biotechnol (2004) 3.29
Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell (2002) 3.09
Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene (2000) 2.73
Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell (2004) 2.71
Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25). Blood (1999) 1.84
The novel activation of ABL by fusion to an ets-related gene, TEL. Cancer Res (1995) 1.73
Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity. Mol Cell Biol (1998) 1.68
Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate. J Med Chem (2002) 1.56
Eph receptor tyrosine kinases in angiogenesis: from development to disease. Angiogenesis (2004) 1.55
Mining the National Cancer Institute's tumor-screening database: identification of compounds with similar cellular activities. J Med Chem (2002) 1.43
Loss of response to imatinib: mechanisms and management. Hematology Am Soc Hematol Educ Program (2005) 1.40
Eph receptor tyrosine kinases in tumor and tumor microenvironment. Curr Pharm Des (2004) 1.33
The role of tyrosine phosphorylation in cell growth and disease. Harvey Lect (2000) 1.23
Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis. Biochim Biophys Acta (2004) 1.20
Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation. J Med Chem (2005) 1.09
Method for analyzing signaling networks in complex cellular systems. Proc Natl Acad Sci U S A (2004) 1.03
Rapid structure-activity and selectivity analysis of kinase inhibitors by BioMAP analysis in complex human primary cell-based models. Assay Drug Dev Technol (2004) 0.91
A concise and traceless linker strategy toward combinatorial libraries of 2,6,9-substituted purines. J Org Chem (2001) 0.91
Angiopoietin/Tie2 signaling, tumor angiogenesis and inflammatory diseases. Front Biosci (2005) 0.89
A new era in the treatment of erectile dysfunction. Am J Cardiol (1999) 0.87
Chemical genetic approaches to kinase drug discovery. Curr Opin Drug Discov Devel (2005) 0.82
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Large-scale analysis of the human and mouse transcriptomes. Proc Natl Acad Sci U S A (2002) 25.47
Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature (2012) 15.91
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
Coordinated transcription of key pathways in the mouse by the circadian clock. Cell (2002) 14.07
An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem (2009) 12.73
BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources. Genome Biol (2009) 11.17
Discovery of gene function by expression profiling of the malaria parasite life cycle. Science (2003) 10.57
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res (2008) 9.29
Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer (2009) 9.26
Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication. Cell (2008) 8.41
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A (2007) 8.23
Noxious compounds activate TRPA1 ion channels through covalent modification of cysteines. Nature (2007) 7.12
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature (2009) 7.05
Uncovering regulatory pathways that affect hematopoietic stem cell function using 'genetical genomics'. Nat Genet (2005) 6.91
Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature (2008) 6.80
The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science (2011) 6.75
Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res (2008) 6.71
A gene wiki for community annotation of gene function. PLoS Biol (2008) 6.60
MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A (2009) 6.58
A unifying model for mTORC1-mediated regulation of mRNA translation. Nature (2012) 6.44
Adding new chemistries to the genetic code. Annu Rev Biochem (2010) 6.32
Structural genomics of the Thermotoga maritima proteome implemented in a high-throughput structure determination pipeline. Proc Natl Acad Sci U S A (2002) 6.00
DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell (2009) 5.97
Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci U S A (2009) 5.86
Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science (2010) 5.50
Human host factors required for influenza virus replication. Nature (2010) 5.28
Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci U S A (2002) 5.28
Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol (2006) 5.03
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. Proc Natl Acad Sci U S A (2008) 4.80
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov (2011) 4.80
An expanded eukaryotic genetic code. Science (2003) 4.66
A strategy to control transmission of Schistosoma japonicum in China. N Engl J Med (2009) 4.50
A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res (2011) 4.22
Use of a dense single nucleotide polymorphism map for in silico mapping in the mouse. PLoS Biol (2004) 4.08
Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet (2004) 3.96
Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci U S A (2006) 3.83
Addition of a photocrosslinking amino acid to the genetic code of Escherichiacoli. Proc Natl Acad Sci U S A (2002) 3.77
Global analysis of transcript and protein levels across the Plasmodium falciparum life cycle. Genome Res (2004) 3.63
Expression analysis of G Protein-Coupled Receptors in mouse macrophages. Immunome Res (2008) 3.54
The Gene Wiki: community intelligence applied to human gene annotation. Nucleic Acids Res (2009) 3.51
Genetic incorporation of unnatural amino acids into proteins in mammalian cells. Nat Methods (2007) 3.45
Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature (2010) 3.39
Expanding the genetic code. Annu Rev Biophys Biomol Struct (2006) 3.36
A probability-based approach for the analysis of large-scale RNAi screens. Nat Methods (2007) 3.34
A genome-wide RNAi screen for modifiers of the circadian clock in human cells. Cell (2009) 3.27
Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One (2011) 3.23
Gene expression signatures and small-molecule compounds link a protein kinase to Plasmodium falciparum motility. Nat Chem Biol (2008) 3.23
Genome-wide analysis of CREB target genes reveals a core promoter requirement for cAMP responsiveness. Mol Cell (2003) 3.23
A stem cell-based approach to cartilage repair. Science (2012) 3.22
An enhanced system for unnatural amino acid mutagenesis in E. coli. J Mol Biol (2009) 3.20
Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol (2008) 3.18
The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res (2010) 3.16
The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci U S A (2008) 3.13
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. Science (2011) 3.07
The Plasmodium falciparum sexual development transcriptome: a microarray analysis using ontology-based pattern identification. Mol Biochem Parasitol (2005) 3.02
Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell (2008) 3.01
Epidemiology of schistosomiasis in the People's Republic of China, 2004. Emerg Infect Dis (2007) 3.00
Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat Chem Biol (2006) 2.96
A systematic map of genetic variation in Plasmodium falciparum. PLoS Pathog (2006) 2.92
Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat Chem Biol (2011) 2.91
Addition of p-azido-L-phenylalanine to the genetic code of Escherichia coli. J Am Chem Soc (2002) 2.88
Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med (2010) 2.86
Addition of the keto functional group to the genetic code of Escherichia coli. Proc Natl Acad Sci U S A (2002) 2.84
Reprogramming of murine fibroblasts to induced pluripotent stem cells with chemical complementation of Klf4. Proc Natl Acad Sci U S A (2009) 2.80
Expanding the genetic code. Angew Chem Int Ed Engl (2004) 2.78
Genomically recoded organisms expand biological functions. Science (2013) 2.73
mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin. Science (2013) 2.71
In situ kinase profiling reveals functionally relevant properties of native kinases. Chem Biol (2011) 2.69
Genetic diversity in yeast assessed with whole-genome oligonucleotide arrays. Genetics (2003) 2.68
Self-renewal of embryonic stem cells by a small molecule. Proc Natl Acad Sci U S A (2006) 2.65
Genetical genomics: spotlight on QTL hotspots. PLoS Genet (2008) 2.63
Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nat Med (2007) 2.62
BioGPS and MyGene.info: organizing online, gene-centric information. Nucleic Acids Res (2012) 2.57